Preadministration of a T-suppressor factor enhances tumor immunity in DBA/2 mice.
Previously we have described the isolation and characterization of a T-suppressor factor (TsF) from a T cell hybridoma (A10F), which has a degree of specificity for the DBA/2 mastocytoma P815. Administration of A10F intravenously at the time of tumor cell injection resulted in an accelerated rate of tumor growth, decreased cytotoxic T lymphocyte antitumor activity, and reduced survival time. In the work reported here, we have shown that administration of affinity-enriched A10F 7-14 days prior to tumor cell injection causes what appear to be reverse effects, in that an enhanced resistance to the P815 tumor is observed in vivo, an effect which we can correlate with the demonstration of antitumor cytotoxic T lymphocyte activity in vitro. These effects are dose-dependent since only doses of TsF at 20 micrograms or greater are effective. A similar effect was found when A10F was administered to DBA/2 mice 10 days prior to challenge with two unrelated tumors (L1210 and M-1). However, when another TsF (Fd11F) with apparent specificity for a nominal antigen was tested in this system, it had no effect on tumor growth.
Deal
H
H
Department of Microbiology, University of British Columbia, Vancouver, Canada.
Steele
J K
JK
Stammers
A T
AT
Singhai
R
R
Levy
J G
JG
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D005260:Female; D007113:Immunity, Innate; D007939:Leukemia L1210 / Q000276:immunology; D008213:Lymphocyte Activation; D012515:Mast-Cell Sarcoma / Q000276:immunology* / Q000628:therapy; D051379:Mice; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D011292:Premedication; D012513:Sarcoma, Experimental / Q000276:immunology* / Q000628:therapy; D013491:Suppressor Factors, Immunologic / Q000008:administration & dosage*; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000276:Adjuvants, Immunologic; D013491:Suppressor Factors, Immunologic